Dr. Sanders has served as a member of the Ultragenyx Board since June 2021. Most recently, she served as Executive Vice President of Development Operations at Juno Therapeutics and strategic advisor to the Office of the Celgene Chief Medical Officer, following Celgene’s acquisition of Juno. She also served as Transition Advisor to the Clinical Development team at Bristol Myers Squibb (BMS), which acquired Celgene. Prior to her role at BMS, Dr. Sanders held numerous leadership positions over the course of 23 years at Genentech/Roche, including serving as Senior Vice President, Global Head of Clinical Operations and Industry Collaboration, for six years. Throughout her career in the biopharma industry, Dr. Sanders has contributed to the development of dozens of therapies across a wide range of indications. She has led the strategy and implementation of hundreds of clinical trials in more than 70 countries and regulatory jurisdictions. She currently serves as a member of the Board of Directors of several biotechnology companies including Beigene Ltd., Molecular Templates Inc., Legend Biotech Corporation and AltruBio (formerly AbGenomics) Inc. She is a member of the Board of Trustees and Chair of the Research Ethics Committee for the Fred Hutchinson Cancer Research Center. Dr. Sanders graduated magna cum laude from the University of the Philippines where she earned a B.S. and M.S. in statistics. She also earned an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.